Different Doses of Naronapride vs. Placebo in Gastroparesis

Summary

This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.

Timeline

Start

2023-01-03

Primary completion

2025-08-12

Completion

2025-09-04

Outcome

Met primary endpoint

release “MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo” drfalkpharma.com ↗

Drugs

Indications